Your browser doesn't support javascript.
loading
Interrogating two schedules of the AKT inhibitor MK-2206 in patients with advanced solid tumors incorporating novel pharmacodynamic and functional imaging biomarkers.
Yap, Timothy A; Yan, Li; Patnaik, Amita; Tunariu, Nina; Biondo, Andrea; Fearen, Ivy; Papadopoulos, Kyriakos P; Olmos, David; Baird, Richard; Delgado, Liliana; Tetteh, Ernestina; Beckman, Robert A; Lupinacci, Lisa; Riisnaes, Ruth; Decordova, Shaun; Heaton, Simon P; Swales, Karen; deSouza, Nandita M; Leach, Martin O; Garrett, Michelle D; Sullivan, Daniel M; de Bono, Johann S; Tolcher, Anthony W.
Afiliação
  • Yap TA; Drug Development Unit, The Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom. Division of Clinical Studies, The Institute of Cancer Research, Surrey, United Kingdom.
  • Yan L; Merck & Co., Inc., Whitehouse Station, New Jersey.
  • Patnaik A; South Texas Accelerated Research Therapeutics, San Antonio, Texas.
  • Tunariu N; CR-UK and EPSRC Cancer Imaging Centre, Division of Radiotherapy and Imaging, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom.
  • Biondo A; Drug Development Unit, The Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom. Division of Clinical Studies, The Institute of Cancer Research, Surrey, United Kingdom.
  • Fearen I; Merck & Co., Inc., Whitehouse Station, New Jersey.
  • Papadopoulos KP; South Texas Accelerated Research Therapeutics, San Antonio, Texas.
  • Olmos D; Drug Development Unit, The Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom. Division of Clinical Studies, The Institute of Cancer Research, Surrey, United Kingdom.
  • Baird R; Drug Development Unit, The Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom. Division of Clinical Studies, The Institute of Cancer Research, Surrey, United Kingdom.
  • Delgado L; Merck & Co., Inc., Whitehouse Station, New Jersey.
  • Tetteh E; Merck & Co., Inc., Whitehouse Station, New Jersey.
  • Beckman RA; Merck & Co., Inc., Whitehouse Station, New Jersey.
  • Lupinacci L; Merck & Co., Inc., Whitehouse Station, New Jersey.
  • Riisnaes R; Division of Clinical Studies, The Institute of Cancer Research, Surrey, United Kingdom.
  • Decordova S; Division of Clinical Studies, The Institute of Cancer Research, Surrey, United Kingdom.
  • Heaton SP; Division of Clinical Studies, The Institute of Cancer Research, Surrey, United Kingdom.
  • Swales K; Division of Clinical Studies, The Institute of Cancer Research, Surrey, United Kingdom.
  • deSouza NM; CR-UK and EPSRC Cancer Imaging Centre, Division of Radiotherapy and Imaging, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom.
  • Leach MO; CR-UK and EPSRC Cancer Imaging Centre, Division of Radiotherapy and Imaging, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom.
  • Garrett MD; Division of Clinical Studies, The Institute of Cancer Research, Surrey, United Kingdom.
  • Sullivan DM; H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
  • de Bono JS; Drug Development Unit, The Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom. Division of Clinical Studies, The Institute of Cancer Research, Surrey, United Kingdom. johann.de-bono@icr.ac.uk.
  • Tolcher AW; South Texas Accelerated Research Therapeutics, San Antonio, Texas.
Clin Cancer Res ; 20(22): 5672-85, 2014 Nov 15.
Article em En | MEDLINE | ID: mdl-25239610
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Inibidores de Proteínas Quinases / Compostos Heterocíclicos com 3 Anéis / Neoplasias / Antineoplásicos Tipo de estudo: Diagnostic_studies / Guideline Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2014 Tipo de documento: Article País de afiliação: Reino Unido
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Inibidores de Proteínas Quinases / Compostos Heterocíclicos com 3 Anéis / Neoplasias / Antineoplásicos Tipo de estudo: Diagnostic_studies / Guideline Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2014 Tipo de documento: Article País de afiliação: Reino Unido